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A Ab bs st tr ra ac ct t
Recently, carriers of biallelic mutations in the base excision repair gene MUTYH, have been demonstrated to have
a predisposition for multiple adenomas and colorectal cancer. Still, many questions remain unanswered concerning
MUTYH. We have addressed the following: Do biallelic MUTYH mutation carriers invariably demonstrate FAP , and
may MUTYH be a gene causing HNPCC, HNPCC-like or dominantly inherited late onset colorectal cancer? 
We examined affecteds from our total series of HNPCC, HNPCC-like and dominantly inherited late onset
colorectal cancer kindreds not demonstrated to have any MMR mutations. Bloodsamples from 96 patients were
subjected to sequencing of exon 7 and exon 13 in the MUTYH gene. Two heterozygotes and one homozygote
for the European founder mutations were found. The homozygous carrier did not meet criteria for FAP/AFAP . 
We conclude that MUTYH, when mutated, causes a rare recessively inherited disorder including colorectal- and
duodenal cancers. It is not verified that heterozygous carriers of MUTYH mutations have an increased risk of
cancer, and they do not explain the occurrence of familial colorectal cancer in the population.
I In nt tr ro od du uc ct ti io on n
Recently, carriers of biallelic mutations in the base
excision repair gene, MUTYH at 1p34.1, have been
demonstrated to have a predisposition for multiple
adenomas and colorectal cancer (CRC) causing
autosomal recessive inherited disease [1]. The gene
encodes a glycolase which is involved in repair of DNA
damage caused by reactive oxygen species generated
during aerobic metabolism [2, 3]. In variant forms this
ability is reduced [4]. Oxidative damage to DNA can
lead to degenerative diseases, aging and cancer [2].
Sequence variants in MUTYH are found in different
ethnic groups [1]. Two common MUTYH mutations,
Y165C and G382D, account for approximately 85%
of the mutations occurring in individuals of Caucasian
ancestry [1]. Other MUTYH mutations known to be
associated with colorectal cancer (CRC) are E466X,
Y90X and 1395delGGA [1, 5]. Combined data from
previous studies suggest that about 1% of colorectal
cancer cases can be attributed to biallelic MUTYH
mutations [3, 6-8]. Families classified as Familial
Adenomatous Polyposis (FAP) or Attenuated FAP (AFAP),
but without a detected mutation in the Adenomatous
Polyposis Coli (APC) gene, may be caused by biallelic
MUTYH mutations [9].  
Phenotypic expression of the MUTYH mutation in
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demonstrated that the MUTYH mutations Y165C,
G382D and 1395delGGA were not present in the APC
mutation-positive FAP population they investigated,
suggesting that it does not act as a modifier gene in
the development of FAP . The mismatch repair genes
also have roles in the removal of oxidative damage
[10]. It is demonstrated that the MSH2/MSH6 complex
is physically associated with MUTYH at an MSH6
binding site and is required to stimulate MUTYH activity
[10, 11]. Disruption of the MSH2/MSH6 complex
causes HNPCC, and it has been reported that MUTYH
mutations are associated with colorectal cancer risk
and can be associated with the clinical features of
HNPCC [9, 12]. Kambara et al. [8] suggest that
MUTYH variation does not initiate progression of
cancer, but acts as a promoter in a subset of CRCs.
Croitoru et al. [13] demonstrated that heterozygous
mutations in Y165C and G382D may confer a
potentially important low-penetrant risk of CRC. 
A number of families fit the clinical criteria for FAP ,
AFAP , HNPCC or appear to be inherited, but mutations
in known genes have not yet been found. About 30%
of FAP cases are apparently “sporadic” (new mutations)
giving a one in two risk to their offspring, but low risk
to their siblings. If these cases are caused by MUTYH
mutations and recessive inheritance, the risk to siblings
is one in four and the risk to offspring is low in small
sibships. The findings have clinical implications for the
families as to evaluating the risk of developing cancer
and mode of surveillance.  
Many questions remain unanswered concerning
MUTYH. We have addressed the following: 1) Do
biallelic  MUTYH mutation carriers invariably
demonstrate FAP? 2) May MUTYH be a gene causing
HNPCC, HNPCC-like or dominantly inherited late
onset colorectal cancer (LOCRC)? 
Previously [14, 15] we have identified a number of
families with aggregation of CRCs and/or colorectal
polyps. We have used the tools available to identify
known CRC syndromes in these families, but in a
majority no definite cause has been demonstrated. We
here report the results of screening these families for
MUTYH mutations.
P Pa at ti ie en nt ts s   a an nd d   m me et th ho od ds s
The patients included in the study had been referred
to the Section of Genetic Counselling at the Norwegian
Radium Hospital. They were included and classified
according to their family history of colorectal and other
cancers applying wide clinical criteria [16]. The family
history was expanded and information on the site and
classification of cancers and polyps and age at diagnosis
were obtained and verified in the medical files and/or
in the National Cancer Registry whenever possible. 
We examined affecteds from our total series of
HNPCC, HNPCC-like and LOCRC kindreds demon-
strated not to have any MMR mutations. Blood samples
from 96 patients diagnosed with either cancer and/or
tubular adenomas were examined. Thirty-one belonged
to HNPCC families, i.e. they met the Amsterdam criteria II
[17]; 43 were HNPCC-like, i.e. they almost met the
Amsterdam criteria II and/or had cases with multiple
primaries; and 22 belonged to families with LOCRC,
i.e. presence in the family of four or more HNPCC-
related cancers all diagnosed over 50 years of age
[18]. Sixty-three index persons had at least one cancer
and 33 index persons had one or more adenomas.
Median age of first tumour was 49 years (23-78) for
colorectal cancers (n=53), 49 years 
(29-76) for tubular adenomas (n=33), 54 years 
(44-62) for endometrial cancers (n=4) and 57 years
(39-69) for other cancers (n=6). 
Tumours from eighty-five affecteds had been
subjected to immunohistochemistry (IHC) for the
presence of MLH1, MSH2 and MSH6 gene products
using standard procedures [14, 15, 19, 20]. Blood
samples from all patients demonstrating lack of gene
product in tumour by IHC (n= 66) had been subjected
to sequencing of the corresponding gene and
searching for large rearrangements in MLH1 and
MSH2 [14, 15, 21].
All blood samples were subjected to sequencing of
exon 7 (Y165C) and exon 13 (G382D) in the MUTYH
gene with PCR reactions as previously described [6]. DNA
sequencing was performed using a DYEnamic ET dye
terminator cycle sequencing kit on a MegaBACE
TM1000
(Amersham Biosciences, Uppsala, Sweden).
The medical files verifying diagnoses were obtained
with written permission from living persons, or with
permission from descendants of the dead ones. Written
informed consent was underlying all requests for tumour
specimens. If the patient was dead, the living relative(s)
at risk consented. For mutation analyses, informed
consent was obtained in writing following genetic
counselling. Because all activity reported was approved
health care, all information was kept in our medical files.
R Re es su ul lt ts s
Two heterozygotes for the European founder muta-
tions were found:
• one patient was heterozygous for G382D. She had
an ovarian cancer at the age of 69 and one colon
adenoma. Her daughter had three tubular adenomas
48 years old, three tubular adenomas 49 years old
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and one at the age of 56, but a blood sample was
not available. The family had been classified as
HNPCC-like. Immunohistochemical staining with
antibodies against MLH1, MSH2 and MSH6 proteins
of the patient’s ovarian cancer showed presence of
all three proteins and mutation analyses for MMR
genes were not undertaken;
• the other patient was heterozygous for Y165C. He had
two tubular adenomas at the age of 49 and a
hypophyseal adenoma at 50. His two siblings had not
had cancers or adenomas. His mother had CRC at
40 years, and endometrial cancer at 50. She
developed duodenal and jejunal polyps demonstrated
to include two invasive cancers, and was demonstrated
to be homozygous for Y165C. Her sister had contrac-
ted CRC at 42. The family had been classified as close
to the Amsterdam criteria II [17]. 
D Di is sc cu us ss si io on n
In our series, selected to have dominantly inherited
colorectal cancer, or suspected to have, we found no
excess of MUTYH mutations. We concluded that the
clustering of colorectal cancers in the families was not
caused by MUTYH mutations.
The prevalence of MUTYH mutations in the series
examined was 2/96=2%, which is not more than
expected by chance alone. Both mutation carriers were
selected because of presence of adenomas, which
consequently could not be included in the analysis of
the mutation carriers. The major clinical findings were,
however, that one of the patients had ovarian cancer
and the other a hypophyseal adenoma. In addition,
the latter had a homozygous mother with HNPCC-like
phenotype including endometrial carcinoma, who later
in life presented with AFAP-like disease. None of the
findings indicated that MUTYH might cause dominantly
inherited HNPCC or LOCRC, and none of the families
included relatives with FAP .
Other studies have shown 1.35-1.67% Y165C and
G382D mutations in a control population [9, 12, 13],
1.6% in HNPCC patients [12] and 2-2.34% in CRC
patients [7, 13]. The numbers are probably
underestimated since the mutation screening methods
do not detect all disease-causing sequence changes.
The carrier frequency in British and North American
populations has been estimated to be 2% [4, 22].
In the first reports on homozygous for MUTYH
mutations having colorectal cancer, patients were
selected on the basis of having multiple polyps (AFAP).
The two heterozygous mutation carriers and also the
homozygous mutation carrier in our study only had a
few adenomas. Others have also shown that
heterozygous and homozygous mutation carriers are not
consistent with multiple adenomatous polyps [6, 7, 12,
13, 23]. It seems like homozygous for MUTYH mutations
may present AFAP , but they do not invariably do so.
The homozygous (Y165C/Y165C) mutation carrier
did not meet the diagnostic criteria for FAP , but
developed duodenal and jejunal polyps. This is keeping
with other reports: [12, 13]. Nielsen et al. [24] revealed
several cases of gastro-duodenal polyps in
homozygous mutation carriers in MUTYH-associated
polyposis coli and Kairupan et al. [9] reported one
patient with a duodenal polyp. 
Farrington et al. [23] demonstrated that heterozygo-
us mutations predispose to CRC later in life, but the effect
was small and of borderline significance. Croitoru et al.
[13] reported that heterozygous MUTYH mutations
(Y165C and G382D) may confer a potentially important
low-penetrance risk of CRC. Such reports should be
interpreted with caution, because when an MUTYH
mutation is found in a colorectal cancer kindred, half of
the affected relatives are expected to have the same
mutation. One might have expected more reports if the
positive finding were true. It is possible that negative
findings have not been reported. None of our LOCRC
families demonstrated MUTYH mutations.
In conclusion, our findings were in keeping with our
interpretation of the literature: homozygous carriers of
MUTYH mutations are at increased risk of colorectal
cancer. They may present FAP or AFAP , but they do not
invariably do so. Heterozygous carriers of MUTYH
mutations may or may not have slightly increased risk of
colorectal cancer, but they do not explain the occurrence
of familial colorectal cancer in the population. From a
practical clinical genetic point of view, MUTYH mutations
cause a rare autosomally recessively inherited disorder
characterized by colorectal and duodenal cancers.
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